Momentum Stock Watch: The Medicines Company (MDCO)

Company Profile:

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The Company’s mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Recent News:

For the first quarter ended March 31, 2018, the company reported that loss from continuing operations on a GAAP basis was $84.8 million, or $1.14 per share, compared to $71.0 million, or $1.00 per share, in the first quarter of 2017. Net income from discontinued operations in the first quarter of 2018 was $114.0 million compared to a net loss of $31.7 million in 2017.

On March 27, 2018, the company announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



MDCO’s strengths can be seen in its strong growth compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic Oscillator. RSI(14) stands at 47.58 with positive bias. We rate The Medicines Company (MDCO) a STRONG BUY.

About the Author

has written 10757 stories on this site.

Copyright © 2012 Nine Stocks